Quantitative Analysis of Favipiravir Spiked in Plasma Using by HPLC
contributed by Shimadzu |
As of 2020, the development of both pharmaceuticals and vaccines remains urgent to overcome the global coronavirus disease 2019 (COVID-19) pandemic. Favipiravir (brand name: Avigan®), a promising drug candidate for COVID-19, is classified as an antiinfluenza drug, evaluated and developed for both novel and re-emerging influenza viruses. (1), (2) Favipiravir undergoes renal excretion, eliminated in the urine mainly as a hydroxide. Notably, the plasma levels of this drug are difficult to control owing to its once daily dosing regimen. (3) Consequently, the accurate monitoring of drug levels is crucial.
Read the full article now
Log in or register to read this article in full and gain access to The Analytical Scientist’s entire content archive. It’s FREE!